After 2 years in operation, John Snow Labs is excited to announce its expansion into the Life Sciences arena, with 68 updated Data Accelerators and 271 Fresh Datasets in this repository. It showcases data from the fields of medical devices, drugs, food and genomics, and will keep expanding to other life science categories.

This new development in John Snow Labs further forges its vision and commitment in contributing to the health of everyone around the world by “ACCELERATING THE USE OF DATA TO IMPROVE HUMAN WELL-BEING”.

An expanded team of healthcare professionals with deep academic and industry expertise has curated the datasets from its research phase to its high-quality, enriched, customer-ready state. The process includes three levels of quality assurance – two manual reviews plus an automated set of over 50 validations. All datasets are now ready and in use across multiple critical stakeholders in the life science ecosystem, from physicians, researchers, managers, regulators, data scientists, financers and financial analysts, legal experts, advocacy groups and government agencies.

How this upgrade from John Snow Labs impacts the Life Sciences industry

• Minimized mistakes and reduced cost of research

• Shortened time spent in gathering data

• Improved lives

• Personalized therapies

• Accelerated research efforts

John Snow Labs’ direction has broad coverage of core biotech and pharma data needs; as well as opportunities to leverage health & life science research from universities and non-government research communities and advocacies. Governments can also find aid in creating cost-efficient, financially sustainable and health effective programs.

John Snow Labs actively bridges the gap between Science and technology

One of the most urgent needs right now is best stated in the World Health Organization’s (WHO) statement on antimicrobial resistance:

“WHO today published its first ever list of antibiotic-resistant ‘priority pathogens – a catalog of 12 families of bacteria that pose the greatest threat to human health.

The list was drawn up in a bid to guide and promote research and development (R&D) of new antibiotics, as part of WHO’s efforts to address growing global resistance to antimicrobial medicines.

The list highlights the threat of gram-negative bacteria that are resistant to multiple antibiotics. These bacteria have built-in abilities to find new ways to resist treatment and can pass along genetic material that allows other bacteria to become drug-resistant as well.” 27 February 2017 WHO, Geneva

John Snow Lab’s is strategically positioned in helping find solutions for this threat, as data is made readily available, research scientist’s work can now be shortened. They can now better focus on finding answers and alternatives, which was previously spent in gathering facts. Time and treatment options are running out and the traditional method of market forces alone will no longer work.

Having all the different sectors working together will assure the general public of better outcomes, wiser decisions, decreased negative consequences, lessened adverse health effects and reduced financial losses.

Here is a snapshot of the categories contained in the Life Sciences Repository:

• Devices: 8 Accelerators and 40 Datasets that include device listings, examinations, classification and recalls, applications and approvals, experiences, adverse events and X-ray assembler data.

• Drug Pricing: 10 Accelerators and 24 Datasets that include drug utilizations, rebates, FDA prescriptions, Federal Upper Limits (FUL), Medicare Public Use Files (PUF) and drug plans, Healthcare Common Procedure Coding System Crosswalks (HCPCS), National Drug Codes (NDC), National Average Drug Acquisition Cost (NADAC), drug distributors and pharmacy locations.

• Drug Safety: 23 Accelerators and 85 Datasets that include drug approvals, discontinuations, schedules, dissolutions, inspections, inactive ingredients, clinical investigations; drug and product adverse reactions, drug and product labels; antimicrobial use and resistance, NARMS isolate level data, Biotech and Pharma databases, FAERS from 2014 to 2016; FDA drug master files, FDA vaccines database, FDA unique ingredient and pill identifiers; NDC Drug labels database, NQF medication measures, drug products from Orange book and biological products from Purple book.

• Drugs: 2 Accelerators and 8 Datasets that include Biotechnology and Pharmaceutical information database and Healthcare Common Procedure Coding System Medicare costs and Crosswalks

• Food: 17 Accelerators and 70 Datasets that include food affordability, nutrition value, mobile food; alcoholic beverages control, healthy eating index, total diet study; statistics on genetically engineered crops, NY open data reports, restaurant inspection scores, farmers market; nutrition assistance program participation and costs; USDA food plans, agricultural projections, apps for healthy kids competition, productivity growth in farm sectors, USDA wheat yearbook and USDA yield and retention data.

• Genomics: 8 Accelerators and 44 Datasets include comparative toxicogenomics database, drug targets and lists, gene products and targets, genes clinical correlations, genetic associations, genetic associations in aging, human gene expression database and immortalized cell lines catalog.

For further information, visit: www.JohnSnowLabs.com

Media Contact:

John Snow Labs
Attn: Ida Lucente
16192 Coastal Highway
Lewes, DE 19958
+1 (302) 786-5227
ida@JohnSnowLabs.com

Media Contact
Company Name: John Snow Labs
Contact Person: Ida Lucente
Email: info@johnsnowlabs.com
Phone: +1 (302) 786-5227
Address:16192 Coastal Highway
City: Lewes
State: Delaware 19958
Country: United States
Website: www.johnsnowlabs.com